AI-guided therapeutics, nanocarrier delivery, and computational biology — engineered for precision, validated through rigorous research.
Tissue-engineered scaffolds and regenerative models.
Folate-targeted liposomal carriers with pH-responsive release.
ML formulation optimization via the AEGIS research console.
Continuous biometric monitoring and health telemetry.
Folate-targeted cancer therapy model.
Post-stroke recovery dynamics.
Research-partner AI infrastructure.
Phytochemical DNA-repair study.
Bio-inspired locomotion platform.
Peer-archived publications.
SynEVOL Inc is a Memphis-based research and development company advancing precision medicine through AI-guided therapeutics, nanocarrier drug delivery, and computational biology. We operate at the intersection of molecular science and machine intelligence — engineering treatments that target disease precisely while sparing healthy tissue. Our work is published, peer-archived, and federally registered, built on verifiable research rather than unsubstantiated claims.
Where conventional medicine floods the body, we target. Folate-receptor delivery and pH-responsive release confine therapeutics to where they are needed.
Our formulations are computationally optimized through the AEGIS console before they ever reach the bench — compressing discovery timelines.
Every claim is mapped to a source: Zenodo DOIs, ORCID attribution, SHA-256 verification, and active federal registration.
Founder & Principal Investigator. Researcher across molecular medicine, AI-guided drug delivery, and computational biology — operating at the intersection of science and engineering.